Message #14 From:
Stock News Bot Date: October 11, 2006 06:15:00 AM
GTHA News GeneThera and Leading Italian Research Institute Finalize Collaboration Agreement on Mad-Cow & Other Animal Diseases
WHEAT RIDGE, Colo.--(BUSINESS WIRE)--GeneThera, Inc. (OTCBB:GTHA) is pleased to announce the finalization,
subject to final translation, of a Collaboration Agreement with Italy’s
leading applied research laboratory, Istituto Zooprofilattico
Sperimentale della Lombardia e dell´Emilia
Romagna (IZSLER) to collaborate on scientific research related to the
diagnosis of animal transmittable diseases, such as Mad-Cow and Scrapie
diseases.
The Parties to this Agreement will endeavor to validate GeneThera’s
proprietary technology by comparing 10,000 samples between GeneThera’s
developed test and an approved Post Mortem test under ESFA guidelines
for validation. Basically, GeneThera will be responsible for supervising
all aspects of the testing under this Agreement, while the Institute
will provide its facilities and assist in the accreditation and
validation of the tests and technology of GeneThera.
The Agreement will allow for the (i) establishment of validation
protocols to compare GeneThera’s live animal
blood test technology for the detection of Transmissible Spongiform
Encephalopathy (“TSE”)
to current available methodologies for “post
mortem detection” of TSE; (ii) to establish a
research protocol for a time course correlation study between the
TSE-specific gene marker expression levels in blood and the presence of
TSE in live experimentally infected animals, and (iii) to establish a
Bovine Spongiform Encephalopathy (“BSE”)
screening program using GeneThera’s live
animal blood test system for large scale cattle testing in feedlots and
slaughter houses.
In conjunction with this announcement, IZSLER has begun collecting the
first samples from the Institutes’s
experimentally infected cattle herd with GeneThera’s
Field Collection System™ for review by
GeneThera’s staff.
Dr. Tony Milici, CEO of GeneThera remarked, “This
is a banner day for our Company. The long-awaited day for us to begin
large scale validation of our live test for detection of TSE is at hand.
We have waited many years for this opportunity and are extremely excited
what the start of this validation means to GeneThera and to the future
of BSE testing.”
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Wheat
Ridge, CO. The Company provides genetic diagnostic solutions for the
veterinary and agricultural industries with future plans to include the
health-care industry. The Company's proprietary diagnostic solution is
based on a genetic expression assay, GEA(TM), a protocol designed to
function on a highly automated Fluorogenic PCR platform. This platform
enables GeneThera to offer tests that are presently not available from
other technologies. The GEA is designed for a host of individual
diseases, the current priority being Mad Cow disease, Chronic Wasting
Disease, a disease affecting elk and deer in North America; E.Coli
0157:H7 and Johnne's Disease, diseases affecting cattle worldwide.
About IZSLER
Istituto Zooprofilattico Sperimentale della Lombardia e dell´Emilia
Romagna (IZSLER),(www.bs.izs.it),
offers a broad range of services in the Public Veterinary sectors in
particular, Food Safety to the Veterinary Services, Breeders and
Consumers. Its functions today can be described as those of a
Technical-Scientific Body providing services as required of it by
national and regional law. At the present, IZSLER employs over 600
persons, 90 of them are graduated scientists (veterinarians, biologists
and chemists). On a regional basis (Lombardia and Emilia Romagna),
IZSLER performs diagnosis for a variety of viral infectious diseases of
ruminants, pigs, horses, poultry and other species of economic interest
(rabbits, fishes, bees....), and microbiological and chemical analysis
on foodstuffs of animal origin destined for human consumption and on
food resources for animals.
“Safe Harbor”
Statement:Certain statements in this release are “forward-looking”
statements as defined in the Private Securities Litigation Reform Act of
1995.Such statements are subject to numerous risks and
uncertainties.Actual results may vary significantly from the
results expressed or implied in such statements.Factors that
could cause actual results to materially differ from forward-looking
statements include, but are not limited to, the Company’s
ability to meet the terms and conditions required to obtain its project
financing, risks and delays associated with product development, risk of
market acceptance of new products, risk of technology or product
obsolescence, competitive risks, reliance on development partners and
the need for additional capital.
